Current Report Filing (8-k)
April 18 2017 - 3:39PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): April 18, 2017
Argos Therapeutics, Inc.
(Exact Name of Registrant as Specified
in Charter)
|
|
|
|
|
Delaware
|
|
001-35443
|
|
56-2110007
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
4233 Technology Drive
Durham, North Carolina 27704
|
|
(Address of Principal Executive Offices)
|
|
Registrant’s telephone number,
including area code: (919) 287-6300
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
Item 8.01 Other Events.
On April 18 2017, the Company issued a press release announcing
interim results from its Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment
of newly diagnosed metastatic renal cell carcinoma and providing additional perspective on its decision to continue the ADAPT trial
notwithstanding the recommendation of the trial’s Independent Data Monitoring Committee that the study be discontinued for
futility. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
On April 18, 2017, the Company will host a conference call to discuss
the interim results of its ADAPT trial and to answer questions. The Company made available a slide presentation to accompany the
call. A copy of the Company’s slide presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The Exhibits to this Current Report on Form 8-K are listed in the
Exhibit Index attached hereto.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARGOS THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/ Jeffrey D. Abbey
|
|
Name:
|
Jeffrey D. Abbey
|
|
Title:
|
President and Chief Executive Officer
|
DATED: April 18, 2017
EXHIBIT INDEX
Exhibit
Number
|
|
Description of Exhibit
|
|
|
|
99.1
|
|
Press Release, dated April 18, 2017, entitled “Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial”
|
99.2
|
|
Slide Presentation, dated April 18, 2017, entitled “Results of February Interim Analysis of ADAPT Study and Perspective on Decision to Keep Trial Open”
|